Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase Ib/II study

被引：0

作者：

Ciruelos, E. M. ^{[1
]}

Hamilton, E. P. ^{[2
]}

Kim, S-B. ^{[3
]}

Im, Y-H. ^{[4
,5
]}

Solis, E. Segui ^{[6
]}

Saenz, J. A. Garcia ^{[7
]}

Di Sanzo, A. ^{[8
]}

Lizarbe, M. Dominguez ^{[9
]}

Wasserman, T. ^{[10
]}

Theall, K. P. ^{[11
]}

Ibrahim, N. K. ^{[12
]}

机构：

[1] Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain

[2] Sarah Cannon Res Inst, Drug Dev Unit, Nashville, TN USA

[3] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea

[4] Sungkyunkwan Univ, Med Dept Hematol, Samsung Med Ctr SMC, Sch Med, Seoul, South Korea

[5] Sungkyunkwan Univ, Med Oncol Div, Samsung Med Ctr SMC, Sch Med, Seoul, South Korea

[6] Hosp Clin August Pi Sunyer Biomed Res Inst IDIBAP, Dept Med Oncol, Barcelona, Spain

[7] Inst Invest Sanitaria Hosp Clinico San Carlos, Dept Med Oncol, Madrid, Spain

[8] Biostatist & Data Management Dept, Menarini Grp, Florence, Italy

[9] Menarini Grp, Clin Res Dept, Florence, Italy

[10] Global Med Affairs Dept, Menarini Grp, Florence, Italy

[11] Global Product Dev Dept, Menarini Grp, New York, NY USA

[12] Univ Texas MD Anderson Canc Ctr, Breast Med Oncol Dept, Houston, TX USA

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.312

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

364P

引用

页码：S370 / S370

页数：1

共 50 条

[41] APOBEC signature, clinical characteristics, and outcome in hormone receptor-positive (HR+) HER2-negative (HER2-) breast cancer (BC) patients (pts) in real-world data (RWD)
Chumsri, Saranya
Raskina, Kira
Sammons, Sarah
Alder, Laura
Danziger, Natalie
Schrock, Alexa B.
McGregor, Kim
Sokol, Ethan
CANCER RESEARCH, 2022, 82 (04)
[42] Preliminary data from a phase I/II, multicenter, dose escalation study of OP-1250, an oral CERAN/SERD, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer
Patel, Manish
Alemany, Carlos
Mitri, Zahi
Makower, Della
Borges, Virginia
Sparano, Joseph
Trinh Le
Klein, Pamela
Lawrence, Julia
Kushner, Peter
Faltaos, Demiana
Harmon, Cyrus
Myles, David
Zujewski, JoAnne
Hamilton, Erika
CANCER RESEARCH, 2022, 82 (04)
[43] SOLTI-1802 ONAWA trial: A window of opportunity trial of onapristone (ONA) in postmenopausal women with estrogen and progesterone receptor-positive/HER2-negative (ER+/PgR+/HER2-) early breast cancer (EBC)
Bellet, M.
Morales Murillo, S.
Gasol Cudos, A.
Amillano, K.
Chic, N.
Gonzalez-Farre, X.
Villagrasa, P.
Ferrero-Cafiero, J. M.
Pascual, T.
Prat, A.
Lange, C.
Saura Manich, C.
ANNALS OF ONCOLOGY, 2021, 32 : S36 - S36
[44] BOLERO-4: Multicenter, open-label, phase II study of everolimus plus letrozole as first-line therapy in ER+, HER2- metastatic breast cancer.
Gradishar, William John
Bachelot, Thomas Denis
Saletan, Stephen
Graham, Anne Marie
Rubini Liedke, Pedro Emanuel
Azevedo, Sergio Jobim
Sriuranpong, Virote
Cardoso, Fatima
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[45] Phase II neoadjuvant study of GDC-9545+palbociclib (palbo) vs anastrozole (A) plus palbo in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2-eBC)
Hurvitz, Sara A.
Fasching, Peter A.
Park, Yeon Hee
Quiroga, Vanesa
Crnjevic, Tanja Badovinac
Fresco, Rodrigo
Lopez-Valverde, Vanesa
Steinseifer, Jutta
Ye, Chenglin
Bardia, Aditya
CANCER RESEARCH, 2021, 81 (04)
[46] Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study
Hurvitz, Sara A.
Bardia, Aditya
Quiroga, Vanesa
Park, Yeon Hee
Blancas, Isabel
Alonso-Romero, Jose Luis
Vasiliev, Aleksandr
Adamchuk, Hryhoriy
Salgado, Marcelo
Yardley, Denise A.
Berzoy, Oleksandr
Zamora-Aunon, Pilar
Chan, David
Spera, Gonzalo
Xue, Cloris
Ferreira, Erika
Crnjevic, Tanja Badovinac
Perez-Moreno, Pablo Diego
Lopez-Valverde, Vanesa
Steinseifer, Jutta
Fernando, Tharu M.
Moore, Heather M.
LANCET ONCOLOGY, 2023, 24 (09): : 1029 - 1041
[47] A phase Ib study of xentuzumab plus abemaciclib and fulvestrant in patients (pts) with advanced hormone receptor-positive (HR+), HER2-negative breast cancer (BC) with visceral or non-visceral disease.
Yee, Douglas
LoRusso, Patricia
Sablin, Marie Paule
Prat, Aleix
Stradella, Agostina
Utriainen, Meri
Oliveira, Mafalda
Yonemori, Kan
Naito, Yoichi
Hardebeck, Molly Catherine
Puig, Marta
Hu, Joy
Biyukov, Tsvetan Nikolov
Iwata, Hiroji
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[48] Phase 2 study of abemaciclib in combination with endocrine therapy with or without paclitaxel induction in patients with hormone receptor-positive, HER2-negative advanced breast cancer and aggressive disease criteria: ABIGAIL
Llombart-Cussac, Antonio
Gligorov, Joseph
Di Cosimo, Serena
Albacar, Cinta
Cortez, Patricia
Duenas, Eduardo Martinez-De
Lopez, Ana
Caranana, Vicente
Medioni, Jacques
Cavanna, Luigi
Cazzaniga, Marina Elena
Braga, Sofia
Coelho, Passos
Sampayo-Cordero, Miguel
Malfettone, Andrea
Perez-Garcia, Jose Manuel
Cortes, Javier
CANCER RESEARCH, 2022, 82 (04)
[49] Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study
Layman, Rachel M.
Han, Hyo S.
Rugo, Hope S.
Stringer-Reasor, Erica M.
Specht, Jennifer M.
Dees, Claire
Kabos, Peter
Suzuki, Samuel
Mutka, Sarah C.
Sullivan, Brian F.
Gorbatchevsky, Igor
Wesolowski, Robert
LANCET ONCOLOGY, 2024, 25 (04): : 474 - 487
[50] H3B-6545+palbociclib in patients (pts) with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (-) breast cancer (BC)
Johnston, Stephen R. D.
Pluard, Timothy J.
Wang, Judy S.
Hamilton, Erika P.
Song, Tingting
Rong, Yuanxin
Yamaguchi, Kohei
Juric, Dejan
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →